Amgen-Sandoz squabble over Neupogen copy could reshape biosim marketing

Tracy Staton

The patent provisions of the Hatch-Waxman Act are familiar to both sides of the branded-generic fence by now. Not so when it comes to similar procedures related to biosimilars. In fact, as a lawsuit  Sandoz's knockoff version of the Amgen therapy  shows, the two sides don't even agree on the rules.


FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS